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EDITORIAL REVIEW
Peritoneal dialysis and loss of proteins: A review
Because of the growing use of peritoneal dialysis (PD), es-
pecially continuous ambulatory peritoneal dialysis (CAPD), it
is increasingly important to explore its benefits and limita-
tions. One of its drawbacks, which has been appreciated for
some time, is the loss of proteins (significantly greater in pen-
toneal dialysis than in hemodialysis) that accompanies the re-
moval of both the low-molecular-weight uremic metabolites
and the so-called middle molecules. The consequences of this
loss have not been explored fully, especially with reference to
proteins of low molecular weight or of slow turnover which can
be assumed to be lost most rapidly.
The heightened nutritional requirements for amino acids and
protein necessitated by their losses during peritoneal dialysis
will not be discussed in detail here; neither will the removal of
middle molecules, considered to be one of the most beneficial
features of peritoneal dialysis. Different investigators fre-
quently assign different upper limits for the middle molecular
weight range, but there appears to be a consensus for a value
somewhere in the low thousands, far below the molecular
weights of most of the proteins dealt with in this review. The
properties and peritoneal dialysis of middle molecules are dis-
cussed in numerous studies and reviews [1—31, Several papers
present recent findings concerning amino acid balance and di-
etary protein requirements in CAPD patients [4, 5].
At the outset it should be noted that thus far claims appar-
ently have not been made that loss of a specific protein (or loss
of a specific class of proteins) via peritoneal dialysis has re-
sulted in a specific metabolic or other deficiency syndrome in
patients. For example, when experience in peritoneal dialysis
was more limited, concern was expressed [6—8] that immune
globulin deficiencies could result due to loss of this group of
proteins via dialysate; to our knowledge, if such a specific re-
lationship does exist, it has yet to be proven. Indeed, it may
not be surprising that relationships of this type have not yet
been demonstrated, given the limited number of proteins ex-
amined, the likelihood that various systems in patients who re-
quire prolonged dialysis therapy may already be adversely af-
fected, and the possibility that the experience of many patients
on peritoneal dialysis may have been so short-lived that these
problems have not yet had time to develop. Furthermore, the
benefits conferred by peritoneal dialysis appear to offset the
risks in certain areas, at least to some degree; to continue with
the previous example, the more satisfactory removal of im-
munosuppressive middle molecules by peritoneal dialysis com-
pared with hemodialysis is suggested to be responsible for the
improved immunodeficiency in uremic patients on CAPD [91.
As indicated earlier, a relatively limited census has been
taken of the plasma proteins lost during dialysis. Additionally,
some aspects of protein loss in dialysate, such as its depen-
dence on molecular size, have not received as much attention
in the literature as they may warrant. Therefore, we will dis-
cuss in this review what is known about these and other fac-
tors that bear on protein loss in peritoneal dialysate, hoping
that a better understanding will be gained.
Variables affecting protein accumulation in peritoneal
dialysate
Considerable amounts of protein are removed from the body
during peritoneal dialysis; investigators of one study summa-
rize that "the quantities lost during peritoneal dialysis are simi-
lar to those in 50 to 200 ml of plasma" [101. The amounts of
protein that may be lost during CAPD are roughly between 5
and 15 g/day [10—16]. The quantity has been shown to depend
on the frequency and duration of the dialysis [12, 13, 15—18],
the composition of the fluid infused [12—16, 18—21], the body
surface area [16], the serum protein concentration [10, 16, 22],
and the patient's clinical status [10, 13, 23]. The effects of cer-
tain variables, and the direction of the effects, require no fur-
ther comment, but, at least two areas are less well defined: the
effects of the dialysis solution itself and the clinical status of
the patient.
The effects of solutions used for human peritoneal dialysis
have been examined not only clinically on the removal of sol-
utes during dialysis [19—21, 24], but also experimentally on the
microcirculation of animal vasculature [19, 24—271. In addition
to providing a better understanding of the physiology and phar-
macology of the peritoneal vasculature, it has been suggested
that such studies could enhance "the development of solutions
suitable for differential dialysis of particular solutes" [26]. As
is well known, commercial peritoneal dialysis solutions are
themselves vasoactive and thereby affect solute delivery at the
peritoneum. With regard to protein transport into peritoneal di-
alysate, it has been shown that addition of the vasodilator ni-
troprusside to peritoneal dialysis solutions significantly in-
creased the clearance of larger molecular weight solutes (mu-
lin, protein) proportionately more than it did the clearances of
compounds with lower molecular weights (urea, creatinine). It
is possible that nitroprusside caused these changes "by both a
vasodilatory effect and by an effect on vascular membrane per-
meability and area for solute exchange" [19]. Interestingly, it
was found that protein clearance was increased still more if the
pH of the dialysis solution had been adjusted from the usual
acidic value of 5.6 up to 7.4, in the presence of nitroprusside
[19]. Dialysate protein was also increased proportionately more
than were the clearances of smaller solutes when a more physi-
ological dialysis solution was substituted for the usual commer-
cial solutions; this nonvasoactive solution approximated the
composition of human extracellular fluid in pH, ionic compo-
sition, and buffer [24]. One possible interpretation of these re-
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sults was that an enhanced diffusion of larger solutes occurred
due to a proportionately greater increase in capillary area
and/or permeability than in capillary flow, since the initial
vasoconstriction (known to be caused in animal peritoneum by
commercial dialysis solutions) was prevented [24]. It has been
noted that "repeated exposure to vasoactive solutions appears
not to cause irreversible constriction or dilation" [20]. In sum-
mary, the results gathered from these studies so far indicate
that the amount of protein entering dialysate is influenced by
combinations of the high osmolality, the nonbicarbonate buffer
anions, and the acidic pH of the commercial dialysis solutions
[21, 24]. The exact mechanisms by which these (and possibly
other) variables interact to affect vascular area and/or perme-
ability remain to be determined.
The clinical status of the patient on peritoneal dialysis may
be relevant in several ways to a loss of protein. In the first
place, considerable attention has been given recently to the
longterm effects of peritoneal dialysis on the clearances of vari-
ous solutes [20, 28—33]. Apart from the question of longterm ef-
fects on the clearance of small solutes (compare, for example,
[28] with [20] and [31]), reports agree that there is no signifi-
cant change in peritoneal transport as assessed by dialysate
protein concentration over 1- [20, 30] or 2-year [32] periods.
The question of whether peritonitis affects the passage of pro-
tein into peritoneal dialysate has been resolved as follows: The
immediate result of peritonitis is to enhance loss of protein [10,
13, 20, 30], while on the other hand there seem to be no sig-
nificant longterm changes [20, 32]. (The effect of inflammation
on peritoneal membrane permeability is thus similar to its ef-
fect on human synovial membrane, where greater inflamma-
tion is accompanied by augmented transmembrane passage of
proteins, with, incidentally, a proportionately greater increase
in permeability to larger proteins [34].) Patients with systemic
vasculitis [35] or with scleroderma [36] who undergo perito-
neal dialysis have reduced clearances of small solutes; it would
be interesting to evaluate the loss of protein into dialysate in
such patients. It also remains to be determined to what extent
the permeability of vascular membranes is under hormonal in-
fluence; some influence is implied from studies of peritoneal
fluid constituents throughout the menstrual cycle [37, 38], and
by studies of gastrointestinal hormones and peritoneal trans-
port in rabbits [39].
A number of compounds have been implicated in vascular
permeability changes including those that accompany inflam-
mation, and may be mentioned as they might play a role either
in normal peritoneal transport, or in the increased protein
losses associated with peritonitis, or both. Histamine and
bradykinin both increase peritoneal clearances of urea and mu-
un in rats [25], and histamine increases the permeability of iso-
lated rat mesentery to albumin and inulin [40]; it has been pro-
posed that such effects of histamine and bradykinin can be ac-
counted for by an increase in the size and volume turnover of
endothelial vesicles [411. Arachidonic acid, a precursor of pros-
taglandins, increases peritoneal clearances of urea and creati-
nine in rabbits [42]; a related point is that experiments using
rabbit skin have indicated that inflammatory plasma exudation
may be due to the synergistic action of permeability media-
tors, specifically complement-derived peptides such as C5a and
C5a des Arg, and vasodilator mediators, in this case
prostaglandin(s) [43—45]. Finally, leukokinins appear to be in-
volved in the formation of ascites [46, 47].
The interactions between a number of drugs and peritoneal
transport have been reviewed [48].
A detailed discussion of the structures and processes pos-
sibly involved in protein transport between the vascular and
lymphatic compartments and the peritoneal space is beyond
the scope of our review; however, a number of studies or
reviews are available which provide background in various as-
pects of this subject: (1) structure and permeability of mi-
crovascular endothelium [49—54]; (2) structure and permeabil-
ity of basement membrane and interstitium [55—60]; (3) struc-
ture and permeability of mesothelium [61—65]; (4) communica-
tion between the lymphatics and the peritoneal space [66, 67];
and (5) speculations on how these structures and processes
participate in solute transfer during peritoneal dialysis [68—73].
Intraperitoneal sources of dialysate protein
It should be noted that one potential source of proteins in
peritoneal dialysate which has received little attention in the lit-
erature is their local production in or adjacent to the perito-
neal space itself. Local production of immunoglobulin G (IgG)
in the cerebrospinal fluid space [74] and in the rheumatoid
synovium [75] during certain inflammatory processes has been
recognized for some time. It is likely that fibronectin (found in
basement membrane and interstitium) can also be locally pro-
duced in cerebrospinal [761 and synovial [77, 78] fluids. It can
be speculated that peritoneal fluid and dialysate proteins could
likewise result from synthesis by cells indigenous to peritoneal
fluid (macrophages, lymphocytes, polymorphonuclear leuko-
cytes, and so forth [16, 79, 801) as well as from the mesothelial
cells and fibroblasts involved in the normal renewal or the re-
pair (following peritonitis, for example) of the surrounding
membrane [81]. Polymorphonuclear leukocytes [82] and acti-
vated macrophages [831 produce an array of proteases and acid
hydrolases whose production increases and which are released
extracellularly especially during inflammatory processes; peri-
toneal macrophages also secrete functionally active comple-
ment components [84]. Cultured mesothelial cells synthesize
collagen [85], and collagen and fibronectin are produced by ex-
perimental peritoneal granulation tissue [861. In addition to the
products of normal synthesis, it seems likely that in some pa-
tients peritoneal dialysate would contain cell components re-
leased as a result of pathological ultrastructural changes in the
peritoneum [72, 73] which may be due to peritonitis [87]. The
adverse effects of the nonphysiological components and pH of
commercial peritoneal dialysis solutions on the function of poly-
morphonuclear leukocytes [88] encourages the further specu-
lation that some cells resident in the peritoneal space might not
be able to maintain their integrity in such an environment, at
least early after a dialysis change before the pH and osmolal-
ity have equilibrated; such cell breakage could also contribute
to dialysate protein. The close proximity of lymphatics to the
peritoneal space is probably largely responsible for the entry of
lipoproteins into peritoneal dialysate [6, 89, 90] (and into peri-
toneal fluid in experimental rabbits [64]).
Strong evidence has in fact been presented for the local pro-
duction (and loss in peritoneal dialysate) of one peritoneal pro-
tein. During a study of four patients undergoing peritoneal dial-
ysis, it was found that protein-bound hydroxyproline (col-
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lagen) was present in dialysate in greater amounts than in se-
rum, relative to total protein; the mean serum level was 0.153
mg protein-bound hydroxyproline per milligram of total pro-
tein, whereas the mean level in dialysate was 0.218 mg per
milligram of total protein [91]. Probably related to this finding
is the observation in four patients that removal rates of free
fatty acids in peritoneal dialysate were too high to be ac-
counted for by simple diffusion from plasma, suggesting in-
stead their local generation from lipolysis of adjacent adipose
tissue [92].
Serum proteins whose loss into dialysate has been
quantitated, and dependence of the loss on molecular size
A considerable variety of proteins, representing several
functional classes, have been found in peritoneal dialysate. The
following are some of the individual proteins whose loss into
dialysate has been quantitated: albumin [6, 7, 10, 93, 94]; the
immunoglobulins IgA, lgG, and 1gM [8, 10, 161; complement
factors C3 and C4 [101; transferrin [10]; and PTH and vitamin
D-binding protein [95]. Data in these studies demonstrate two
characteristics of protein loss via peritoneal dialysis: (1) on the
average, for a group of patients the mean loss of a protein is
approximately proportional to its molecular weight; while at
the same time, (2), in different individuals the relative amounts
of different proteins lost may vary over a wide range, irrespec-
tive of the relative molecular weights of the proteins.
The latter characteristic is seen in the results of calculations
that can be made using data from Table 3 of [10], Table 2 of
[8], and Table 2 of [16]. The ratios of IgG/IgA lost in perito-
neal dialysate varied in eight patients from 3.7 to 16.2 [10], in
ten patients from 0.73 to 16.6 [81 and in four patients from 1.4
to 5.7 [16]. In one of these studies [101 for which losses of
seven different proteins were evaluated, the ratios of
albumin/(protein) showed the following variations among the
eight patients: albumin/IgG, 7.4-fold; albumin/IgA, 4.2-fold;
albumin/IgM, 15.2-fold; albumin/transferrin, 1.9-fold; albu-
min/C3, 2.2-fold; and albumin/C4, 3.2-fold.
The first characteristic mentioned above, that is, a rough cor-
relation between the amounts of different proteins lost into
peritoneal dialysate, and their molecular weights, can be seen
from the data in Table III of [96] and Figure 2 of [12], which
give dialysate-to-plasma concentration ratios relative to mo-
lecular weights, and which demonstrate that the lower the mo-
lecular weight of the protein, the higher its concentration in di-
alysate compared to plasma. (An analysis of 23 plasma pro-
teins in peritoneal ascites fluid has disclosed the same inverse
relationship, between the molecular weight of the protein and
its concentration in ascites versus plasma [97].) The peritoneal
membrane thus resembles in this respect other body fluid bar-
riers, such as those that participate in the formation of cere-
brospinal fluid [98] and synovial fluid [991. Parameters af-
fecting passage of proteins through human body fluid barriers
have been reviewed [100]; it should not be forgotten that shape
and charge are also important determinants of transport selec-
tivity [41, 981. (The selectivity of the peritoneal membrane and
other membranes to proteins is discussed in this review in
terms of molecular weight, although the term hydrodynamic
volume would probably be more accurate [98]; this distinction
should be kept in mind, but we will continue to use the former
Table 1. Loss of proteins into peritoneal dialysate as a function of
their molecular weight
Protein
Molecular
weight
Loss per day, as % of
estimated serum (or
extracellular") protein
Refer-
ences
PTH 7 to 9,000 13.6%" 95
Albumin 65 to 69,000 5.4% 10
Transferrin 76 to 90,000 4.9% 10
IgG 150 to 153,000 3.0% 10
IgA 160 to 162,000 2.6% 10
C3 185,000 2.2% 10
C4 209 to 230,000 2.2% 10
1gM 1,000,000 1.0% 10
Total protein — 4.4% 10
All patients were treated with CAPD: three to five infusions, of 2
liters each, per 24 hr.
term since it is the most readily available parameter of size for
these compounds.)
An example of what this molecular weight dependence of
protein transport means in practical terms to the patient on
CAPD is shown in Table 1. The losses per day have been cal-
culated using (1) the mean amounts of protein present in dialys-
ates obtained during 24 hr, as given in Table 3 of [10], and (2)
the mean serum concentrations of the proteins, with an as-
sumed total serum volume of 3 liters. PTH losses were de-
rived from clearance studies [95]. From these data it is clear
that the lower the molecular weight of the protein, the greater
the loss as a percentage of the circulating or extracellular
stores.
Thus, while loss of a given macromolecule is to some extent
predictable on the basis of its molecular weight, it is partly not,
depending presumably among other factors on the rate of bio-
synthesis, on serum concentration in individual patients, on the
patient's clinical status as it affects the permeability of perito-
neal microvasculature, and on the rate of re-uptake by lympha-
tics in the region.
The loss of a given protein during peritoneal dialysis has
been referred to thus far in terms of its percentage of circulat-
ing or extracellular protein, although a more meaningful com-
parison would probably be one with the body's daily rate of bio-
synthesis. This comparison can be made for five proteins. Pro-
tein losses in Table 2 are taken (or calculated in the case of [8])
from data in the references cited; the rates of synthesis per day
[101—104] are calculated for the 70-kg individual.
It can be seen from this comparison that it is possible for the
loss of a particular protein during peritoneal dialysis to ap-
proach or exceed the amount of that protein which healthy per-
sons synthesize under normal conditions; and it need hardly be
pointed out that the amount of protein potentially synthesized
under the best of conditions is limited by nutritional factors
(such as availability of amino acids and enzyme cofactors, that
is, vitamins and minerals) which are themselves subject to de-
pletion via peritoneal dialysis. It appears that in general, dur-
ing the same period of dialysis, protein losses using CAPD are
less than when using intermittent peritoneal dialysis (IPD) [10],
although on a weekly basis losses by CAPD patients would be
greater. The highest losses of immunoglobulins cited in Table
2 [8] were observed during dialysis using 2-liter volumes ex-
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Table 2. Comparison of loss of proteins into peritoneal dialysate with their rate of synthesis
Protein Status or treatment
Rate of synthesis
per day Loss (and number of studies) References
Albumin Normal
Maintenance IPD
Acute IPD
CAPD
8.4 to 14. g
—
—
—
—
8.5 1.5 g/dialysis (54)
13.3 2.4 g/dialysis (23)
5.7 0.4g/day(llO)
101
10
10
10
IgG Normal
Maintenance IPDa
Maintenance IPD"
Acute IPD
CAPD
CAPD
Peritoneal dialysis
2.52 g
—
—
—
—
—
—
—
1.28 0.29 g/dialysis (54)
1.30 0.15 g/dialysis (13)
2.87 0.78 g/dialysis (24)
1.25 0.20 g/day (110)
0.85 — 3.0 g/day (4)
10.6 g/day (10)
102
10
10
10
10
16
8
IgA Normal
Maintenance IPDa
Maintenance IPDb
Acute IPD
CAPD
CAPD
Peritoneal dialysis
1981 mg
—
—
—
—
—
—
182 26 mg/dialysis (54)
392 63 mg/dialysis (13)
547 189 mg/dialysis (21)
173 21 mg/day (110)
180 — 901 mg/day (4)
2580 mg/day (10)
102
10
10
10
10
16
8
1gM Normal
CAPD
Peritoneal dialysis
154 mg
—
—
—
71 18mg/day (110)
440 mg/day (10)
102
10
8
Transferrin Normal
Normal
Maintenance IPD
CAPD
742 mg
1540 to 2100 mg
—
—
—
—
265 31 mg/dialysis (12)
333 22 mg/day (110)
103
104
10
10
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; IPD, intermittent peritoneal dialysis.
a,b Dialyses were performed at two different centers.
changed every 30 mm over 24- to 48-hour periods; the authors
noted that these losses would represent a high proportion of the
immunoglobulin production.
Serum levels of proteins during their loss in perironeal
dialysate
In view of the possible extent of protein losses, it would
clearly be desirable to know how well serum levels of macro-
molecules are actually maintained during peritoneal dialysis.
Conclusions differ on this question; one factor which probably
contributes to the problem is that the degree of depletion ap-
pears to vary from patient to patient [10]. It has been reported
that total protein and serum albumin levels "remain stable"
[14], that serum albumin is maintained "in the low-normal
range" [15], that there is "progressive hypoproteinemia and
hypoalbuminemia" [7], and that "the plasma y-globulin con-
centration fell during dialysis, but recovered fairly rapidly"
while "the plasma albumin concentration fell significantly dur-
ing the period of dialysis" [61. One study reports that the albu-
min level of patients on CAPD "is maintained at the 'ower lim-
its of normal" and that "serum protein and serum transferrin
levels are decreased" [105], while another study which fol-
lowed serum concentrations of total protein, albumin, trans-
ferrin and complement component C3 before and during CAPD
found that the "only significant change was an initial increase
in transferrin levels" [106]. In comparing acute and mainte-
nance IPD, it was found that in the former, "serum protein
concentrations . . . showed no change in total protein, albu-
mm, IgG, IgA, 1gM, transferrin, C3 or C4," while in the latter
"there were no changes in any serum protein measured except
transferrin, which decreased by 4% (P < 0.01)" [10]. The se-
rum levels of PTH fell in four patients during 6 months on
CAPD, but did not change in four others [95]; in the same study
it was found that serum levels of vitamin D-binding protein
were maintained within the normal range, and were in fact
higher than those of matched hemodialysis patients. Serum
gastrin levels have been shown not to decrease appreciably de-
spite the loss of gastrin in dialysate [107]. A study comparing
47 patients on CAPD with 72 patients on hemodialysis showed
that those patients undergoing CAPD had serum IgG, 1gM,
albumin, and total protein values roughly in the middle to low
normal range, although they were significantly lower than cor-
responding values in patients on hemodialysis; serum C3 and
C4 concentrations on the other hand were actually higher than
found in normal subjects or in the patients on hemodialysis
[108]. Finally, the experience gained at one center during 2 to
3 years of CAPD indicated that despite significant decreases at
6 months for serum albumin, IgG and total protein, over the pe-
riod of study serum proteins could be maintained at acceptable
levels [109].
Notwithstanding the diversity among some of the conclu-
sions summarized above (much of it probably attributable to
different dialysis types and schedules), this survey indicates
that thus far no precipitous or pathological loss of any of the
serum proteins assayed seems to have occurred generally
among the patients studied during peritoneal dialysis. It would
appear therefore that on the whole (and in the absence of Se-
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rious impairment of liver function, such as cirrhosis, resulting
in decreased protein synthesis), malnourishment due to pro-
tein loss in dialysate can be compensated by adequate intake
of nitrogen [7, 10, 15, 109]. These findings nevertheless do not
eliminate the possibility that in individual cases, net losses of
individual serum proteins can occur either temporarily or over
a period of time. In addition, the proteins mentioned here ob-
viously represent a very small portion of the total population
present in serum.
It should be noted that some of the protein removal via pen-
toneal dialysis can involve abnormal protein as well as normal,
and can therefore actually be therapeutic. For example, dial-
ysis has been utilized to remove IgG paraprotein in primary
amyloidosis [1101, and IgG paraprotein [Ill] and Bence-Jones
(IgA) protein [1121 in multiple myeloma, although plasmapher-
esis was found to be preferable in the last case. In addition, it
may well be that nonfunctional protein, protein subunits, or
protein complexes are removed by this route which otherwise
would persist in the circulation longer than normal, interfering
with normal homeostatic mechanisms. This could be particu-
larly useful in the event of impaired liver or reticuloendothelial
function. For example, it appears that abnormally increased
amounts of a heterogeneous population of desialylated
glycoproteins is present in serum of patients with cirrhosis,
which are capable of interfering with hepatocyte uptake of gly-
coprotein [1131; removal of such proteins, if they are function-
ally useless, should be beneficial. The very useful removal of
unwanted middle molecules via peritoneal dialysis has already
been alluded to.
Proteins identuied in peritoneal dialysate or peritoneal fluid
Table 3 lists the proteins which have been reported in hu-
man peritoneal dialysate or fluid, making them candidates for
close scrutiny when patients treated with peritoneal dialysis
present evidence of problems possibly attributable to a deple-
tion of one or several of these macromolecules. They have
been classified into major categories in terms of function; their
molecular weights have been taken from several sources [97,
114] as well as from the general literature. Where disagree-
ment exists among the sources, the range is given without at-
tempt to rationalize the values. The type of fluid is listed in Ta-
ble 3, together with a brief description of the disoruer, if any,
associated with the individuals in the study. In many cases, the
entries under the Amount Present heading are limited to the
concentration of the protein in dialysate or fluid, and the ratio
of its plasma and fluid concentrations, because the volume of
the fluid was not specified or was not precise enough to allow
calculation of the amount that would be lost. For the sake of
completeness, this table includes even malignant proteins
(Bence-Jones, and so forth) that have been reported in perito-
neal dialysate.
A comment should be made about the inclusion of certain
other proteins in Table 3, which so far have been unreported
in peritoneal dialysate. It will be seen that two of the carrier
proteins, three of the hormones and six components of the
coagulative and fibrinolytic system have been reported [115,
1161 in peritoneal fluid of menstruating women, which has been
described as an exudate from the active ovary [116, 1171. The
point of including these proteins here (as candidates for loss
during peritoneal dialysis) is that their appearance in peritone-
al fluid, even if due primarily to temporary local hormonal in-
fluences, seems nevertheless likely to involve similar ultrafil-
tration processes by which they and other proteins would pass
from the vascular system into peritoneal dialysate. While the
passage of these proteins into peritoneal dialy sate may differ in
quantity, it should therefore not differ in kind.
Discussion
From the evidence reviewed here it appears likely that ef-
fluent peritoneal dialysate contains many if not all of the pro-
teins present in serum, and in intestinal lymph as indicated by
the presence of lipoproteins. The amount lost will depend on
the type or length of dialysis, the size of the protein, its serum
concentration, and other factors including the patient's clinical
status; the losses will increase, for example, during episodes of
peritonitis, during which dietary adjustments should be es-
pecially important. As a first approximation, proteins of lower
molecular weight will be depleted most rapidly, possibly too
rapidly for the patient's biosynthetic systems to compensate.
These losses may add to the stresses already affecting the dia-
lyzed patient.
Table 3 illustrates the number and variety of proteins al-
ready known to be lost via penitoneal dialysis. It would be of
interest to assay dialysate for many smaller proteins that have
not yet been sought there, for example, some of the growth fac-
tors whose molecular weights range from around 13,000 (nerve
growth factor) down to around 6,000 (epidermal growth fac-
tor), including the somatomedins (7,000 to 5,000) [120]. (The
even lower molecular weights of some of the hypothalamic
regulatory peptides actually put them into the range of middle
molecules; thyrotrophin releasing hormone, a tripeptide, has a
molecular weight of 422 [121].) The amounts of individual pro-
teins lost in peritoneal dialysis are known in relatively few cas-
es and the same is true concerning the effects on their corre-
sponding serum levels. More information might be sought con-
cerning hormones and other proteins synthesized by organs or
tissues other than the liver, which, judging from the albumin
data, can generally manage to cope with the need for in-
creased synthesis of at least some of its products.
In addition to a search for those proteins which, for what-
ever reason such as a slow rate of biosynthesis, might become
seriously depleted in dialysis patients generally, it must also be
considered that the more than tenfold variability (from one pa-
tient to another) in the ratio between the amounts of different
proteins lost, indicates that unpredictable losses are likely to
occur in the individual patients.
The results of various investigations now in progress may
help to diminish the losses of proteins in dialysate, or to better
cope with this loss; sorbent peritoneal dialysis might result in
less protein removal [122], and the use of amino acids as os-
motic agents (rather than glucose) might improve nitrogen bal-
ance problems [1231. Other possible future solute modifica-
tions have been proposed, to help effect a change in the pro-
tein loss more commensurate with therapeutic goals, involving
the addition of vasodilators or vasoconstrictors to peritoneal
dialysate, tailored to individual cases [124].
CAPD offers an important alternative therapy for the treat-
ment of the patient with endstage renal disease. The variety of
proteins found in peritoneal dialysate (Table 3) is somewhat
reminiscent of the proteins lost in the urine of patients with the
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Table 3. Proteins of pentoneal dialysate or peritoneal fluid
Protein, molecular wt
Carrier proteins
(1) Ceruloplasmin, 132 to 160,000
(2) Sex hormone-binding globu-
un, 65,000
(3) Transcortin, 51,700 to 58,500
(4) Transferrin, 76 to 90,000
(5) Vitamin D-binding protein,
—57,000
Concentrated PD from pts with re-
nal failure
PF, in 61 normal women, collected
from pouch of Douglas; mean blood
contamination estimated to be 4.2%
See (2); 68 subjects
PD, from pts with renal failure treat-
ed with CAPD; and AF (=PF) accu-
mulated during interdialytic interval,
from pts undergoing IPD
PD, 5 pts with chronic uremia
PD, 10 pts with renal failure
Trace amounts
PF level 11.2 0.5 sg/1iter; plasmalPF ratio
1.48
PF level 24.1 0.7 mg/liter; plasmalPF ratio 1.42
For CAPD, loss was 333 22 mg/day; for main-
tenance IPD, serum/AF ratio —-2.24
Present
6.2 2.2mg removed with each 1.5% dextrose
exchange
115
10; see also 118
Hormones
(6) Follicle stimulating hormone,
35,000
(7) Gastrin, 3839
(8) Luteinizing hormone, 28,260
(9) Prolactin, 21,500
(10) PTH, 7 to 9,500
See (2); 93 subjects
PD, from 7 uremic pts
See (2); 40 subjects
See (2); 86 subjects
See (5)
PF level 1.9 0.1 mU/ml; plasma/PF ratio 1.58
Serum/PD ratios 2.43 to 12.5; "no appreciable
decrease in serum gastrin levels"
PF level 2.0 0.4 mU/mi; plasma/PF ratio 2.4
PF level 1.2 0.1 mU/ml; plasmalPF ratio 2.8
Estimated mean clearance of immunoreactive
PTH (intact +carboxyl-terminated) was 1.5
0.73 ml/min; daily removal was 13.6 3.2% of
estimated total extracellular PTH. Electropho-
retic profile of i-PTH was similar in dialysate
and serum.
115; see also 38
107
115; see also 38
115; see also 38
95
Coagulative and fibrinolytic system
(11) Antithrombin III (Heparin co-
factor), 65,000
(12) Factor I (Fibrinogen), 341,000
(13) Factor II (Prothrombin),
68,700 to 70,200
(14) Factor V, 310 to 400,000
(15) Factor VIII, 200,000 to
1,120,000
(16) Factor Vill-related antigen
(17) Plasminogen, 81,000
PF, 6 pts with renal failure; in resid-
ual fluid aspirated at end of 48-hr in-
terdialytic interval
PF, in 24 normal women, collected
from pouch of Douglas
See (12)
See (12)
See (12)
See (12)
See (12)
PF activity no more than one-third of normal
plasma activity
PF level, 0.45 0.04 glliter; plasma level, 2.42
0.11 g/liter
PF level was —45% of plasma level
Ranged from below the lower limit of the test to
20% of plasma activity
Levels near the lower limit of the test, mostly
less than 1% of plasma levels
Present at a maximum of 12% of normal plasma
levels
PF level 42.7 0.9% of normal plasma levels
Immune system
(18) C3, 185,000
(19) C4, 209 to 230,000
(20) IgA, 160 to 162,000
IgA paraprotein (Bence-
Jones)
(21) IgG, 150 to 153,000
IgG paraprotein (lambda
type)
IgG paraprotein (kappa type)
See (4), reference 10
See (4), reference 10
PD, from 4 pts with chronic renal
failure; no peritonitis, minimal
erythrocytes
See (4), reference 10
PD, 10 pts with chronic renal fail-
ure; 20 to 40 exchanges during 1 to 2
days; interdialytic interval 4 days to
3 weeks
PD, pt with multiple myeloma
See (20), reference 16
See (4), reference 10
See (20), reference 8
PD, pt with multiple myeloma
PD, pt with primary amyloidosis and
renal failure
For CAPD, loss was 70 7 mg/day; for mainte-
nance IPD, serum/AF ratio —5.0
For CAPD, loss was 21 2.1 mg/day; for main-
tenance 1PD, serum/AF ratio —3.2
Daily losses for the 4 pts, 180 to 901 mg
For CAPD, loss of IgA was 173 21 mg/day;
for maintenance IPD, serum/AF ratio —2.94
Mean IgA loss through dialysis, 2.58 g/day
Gram quantities were removed at each dialysis
Daily loss for the 4 pts, 848 to 2990 mg
For CAPD, loss of IgG was 1.25 0.20 g/day;
for maintenance IPD, serum/AF ratio —2.63
Mean IgG loss through dialysis, 10.6 g/day
22 g removed during 50 2-liter exchanges over 3
days
Present
10
10; see also 12
16
10
8; see also 12,
23, 118
112
16
10
8; see also 12,
118
111
110
Source and medical status Amount present References
118
115
12
95
119
116
116
116
116
116
116
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Table 3. (Continued)
For CAPD, loss of 1gM was 71 18 mg/day; for
maintenance IPD, serum/AF ratio —4.03
Mean 1gM loss through dialysis, 440 mg/day
Enzymes
(23) Acid phosphatase
(24) Adenosine deaminase
(25) Alanine aminotransferase
(26) Alkaline phosphatase
(27) Aspartate aminotransferase
(28) y-Glutamyl transferase
(29) Guanase
(30) f3-Hydroxybutyrate dehydro-
genase
(31) Lactic dehydrogenase
PD, 21 pts with renal failure
See (23)
See (23)
See (23)
See (23)
See (23)
See (23)
See (23)
See (23)
Present
Present
Present
Present
Present
Present
Present
Present
Present
96
96
96
96
96
96
96
96
96
Lipoproteins
(32) HDL
(33) LDL, >1,000,000
/3-lipoprotein
(34) VLDL
(35) Apoprotein A
(36) Apoprotein B
(37) Apoprotein C
PD, in 4 pts with ehdstage renal dis-
ease
See (32)
PD, 12 pts with renal failure
See (32)
See (32)
See (32)
See (32)
Present (loss of HDL cholesterol 1.9 0.8 mg/
hr)
Present (loss of 2.7 1.3 mg cholesterol/hr in
LDL and VLDL combined)
Present
Present
ApoAl and ApoAll identified in HDL and LDL
Present
ApoCli and ApoCill identified in LDL and
HDL
For pts on CAPD, loss of albumin in dialysate
(mean of 110 studies) was 5.7 0.4 g/day; for
pts on (10 hr) maintenance IPD, serum/AF ratio
—2.0
Loss of i.v.-administered albumin via PD, evalu-
ated by RIA method, was 0.8 to 12.3 g/6 hr, but
by different method was 0.3 to 1.0 g/6 hr; this
difference suggested 3 main mechanisms of pro-
tein loss during peritoneal dialysis
Loss in dialysate 31.3 g per dialysis
Loss in dialysate 6.8 to 143.2 g per dialysis
Ratio of protein-bound hydroxyproline/total pro-
tein in dialysate was —30% higher than in serum
(that is, serum/PD ratio was —0.7)
Loss of globulins in dialysate per dialysis: a1,
5.90 3.12 g; a2, 7.67 4.13 g; /3, 7.02 4.46
g; y, 8.74 6.44 g
y-Globulin removal in dialysate amounted "in
some cases to more than two-thirds of the ex-
pected total plasma y-globulin pool"
Present
Present
Present
Present
Abbreviations: AF, ascites fluid; CAPD, continuous ambulatory peritoneal dialysis; IPD, intermittent peritoneal dialysis; PD, peritoneal
dialysate; PF, peritoneal fluid; pts, patients.
nephrotic syndrome [1251. The metabolic disorders that occur
in many patients with the nephrotic syndrome, however, have
failed to develop in the CAPD patient to date (perhaps be-
cause, in addition to urinary losses, nephrotic patients have
disproportionately high rates of protein catabolism [125j). With
the exception of the hyperlipidemia, which is common to both
groups, other diverse complications of the nephrotic patient
such as the iron-resistant microcytic hypochronic anemia, al-
terations in vitamin D metabolism leading to metabolic bone
disease, and hypercoagulability and thrombotic complications,
have been reported infrequently in the CAPD patient despite
the loss of transferrin and vitamin-D binding protein, and the
probable loss of clotting factors, in the dialysate. Many meta-
bolic factors such as protein synthesis to compensate for pen-
toneal protein losses have not been adequately studied in the
CAPD patient, although it is already clear that in the long run,
(22) 1gM, 900,000 to 1,000,000 See (4), reference 10
See (20), reference 8
Protein, molecular wt Source and medical status Amount present References
10
8; see also 12,
16. 23
Miscellaneous
(38) Albumin, 65 to 69,000
(39) Collagen
(40) Globulins
(41) a1-Glycoprotein
(42) a2-Glycoprotein
(43) Pre-albumin
(44) "Seromucoid"
See (4), reference 10
PD, 3 pts with uremia
PD, 7 pts with chronic uremia
See (33), reference 6
PD, 6 pts with renal failure
See (38), reference 7
See (33), reference 6
See (1)
See (33), reference 6
See (1)
See (1)
89
89
6
89
89
89
89
10
94; see also 93
7
6; see also 12
91
7
6
118
6
118
118
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the success of peritoneal dialysis will depend heavily on proper
nutrition. Whether these factors, which are frequently in-
adequate in preventing metabolic complications in the nephrot-
ic patient, will be sufficient protection over extended periods
of dialysis in the CAPD patient must await further observa-
tions. One suspects that a major difference between the two
groups lies in the fact that patients may be nephrotic for many
years while the CAPD experience is still rather short-lived. The
potential mechanism for developing metabolic complications of
various types is certainly present in the CAPD patients and
should be an area of close scrutiny as more patients continue
to have longterm dialysis in years to come.
JOHN T. DULANEY
FRED E. HATCH, JR.
Memphis, Tennessee
Reprint requests to Dr. J. T. Dulaney, Division of Nephrology, Col-
lege of Medicine, University of Tennessee Center for the Health Sci-
ences, 951 Court Avenue, 649D, Memphis, Tennessee 38163, USA
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